Drug intelligence / Profile preview

Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw)

Development stage: Discontinued
Lead developer: Chr. Hansen
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 is an investigational combination of two live probiotic bacterial strains. It was studied by the Medical University of Warsaw in the NCT03032354 clinical trial, a randomized, double-blind, placebo-controlled study in children with newly diagnosed type 1 diabetes mellitus. [1, 7] The intervention aimed to preserve residual pancreatic beta-cell function by modulating the gut microbiota to influence the immune system and prevent further islet cell destruction. [4] The trial results, published in 2021, showed that the probiotic combination did not have a significant effect on maintaining beta-cell function compared to placebo. [2, 3]

Other names: LGG and BB-12 in newly diagnosed type 1 diabetesLactobacillus rhamnosus GG and Bifidobacterium lactis BB12

Targets

TLR9 (Toll-like receptor 9)EGFR (Epidermal growth factor receptor)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw).

Explore the full profile